Tubach F, Hayem G, Marchand J L, Weber M, Palazzo E, de Bandt M, Roux S, Kahn M F, Meyer O
Department of Rheumatology, Bichat Teaching Hospital, University of Paris, France.
J Rheumatol. 2000 Jun;27(6):1437-43.
To investigate the prevalence of serum anti-beta2-glycoprotein I (anti-beta2-GPI) antibodies and other antiphospholipid antibodies (aPL) in patients with systemic lupus erythematosus (SLE). To study their diagnostic value for the antiphospholipid syndrome (APS).
Anti-beta2-GPI and IgG anticardiolipin (aCL) were determined in sera from 102 consecutive patients with SLE using ELISA. Serum and plasma tests were also done for lupus anticoagulant (LAC), syphilis, and antibodies to dsDNA. Clinical and laboratory features of APS were observed.
Prevalences were 23.5% for aCL and 18.6% for anti-beta2-GPI. Correlations between the presence of aCL and anti-beta2-GPI and between their titers were statistically significant (p<0.0001). No associations were found between anti-beta2-GPI and disease activity criteria (SLEDAI, ECLAM, dsDNA). Anti-beta2-GPI were significantly associated with LAC (p = 0.005), APS (p = 0.005), and a high aCL titer (aCL > 5 SD; p< or =0.001). LAC was the best diagnostic criterion for APS.
These data suggest that determination of anti-beta2-GPI in addition to aCL and LAC is unlikely to improve the diagnosis of APS in patients with SLE.
调查系统性红斑狼疮（SLE）患者血清抗β2-糖蛋白I（抗β2-GPI）抗体及其他抗磷脂抗体（aPL）的患病率。研究它们对抗磷脂综合征（APS）的诊断价值。
采用酶联免疫吸附测定法（ELISA）检测102例连续SLE患者血清中的抗β2-GPI和IgG型抗心磷脂（aCL）。还对狼疮抗凝物（LAC）、梅毒及双链DNA抗体进行了血清和血浆检测。观察APS的临床和实验室特征。
aCL患病率为23.5%，抗β2-GPI患病率为18.6%。aCL和抗β2-GPI的存在及其滴度之间的相关性具有统计学意义（p<0.0001）。未发现抗β2-GPI与疾病活动标准（SLEDAI、ECLAM、双链DNA）之间存在关联。抗β2-GPI与LAC（p = 0.005）、APS（p = 0.005）及高aCL滴度（aCL>5 SD；p≤0.001）显著相关。LAC是APS的最佳诊断标准。
这些数据表明，除aCL和LAC外，检测抗β2-GPI不太可能改善SLE患者APS的诊断。
Zotero 插件